ukwelashwa okungewona omncane womdlavuza wamaphaphu eduze kwami

Ukuthola Okulungile Ukwelashwa Ukwelashwa Komdlavuza Wengqamuzana Encane Eduze Kwami

Lo mhlahlandlela ophelele usiza ukuthi uzulazule ezinkingeni zokuthola okusebenzayo Ukwelashwa komdlavuza wamaphaphu ongewona omncane (NSCLC). ongakhetha eduze nawe. Sihlola izindlela zokwelapha ezahlukahlukene, ukucatshangelwa kokukhetha ukunakekelwa okufanele, nezinsiza zokusiza uhambo lwakho.

Ukuqonda Umdlavuza Ongewona Omncane Wengqamuzana Wamaphaphu

Yini i-NSCLC?

Umdlavuza wamaphaphu ongewona omncane uwuhlobo oluvame kakhulu lomdlavuza wamaphaphu, olubalelwa kuma-80-85% azo zonke izifo ezixilongwayo zomdlavuza wamaphaphu. Ihlukaniswe yaba ama-subtypes amaningana, ngalinye linezici ezihlukile ezithinta amasu okwelapha. Ukutholwa kusenesikhathi kubalulekile ukuze kube nemiphumela engcono. Ukuqonda uhlobo lwakho oluncane lwe-NSCLC kuyisinyathelo esibalulekile ekunqumeni inkambo engcono kakhulu ukwelashwa okungewona amangqamuzana amancane omdlavuza wamaphaphu eduze kwami.

Isiteji kanye Nokuxilongwa

Isiteji esinembile—ukunquma izinga lokusabalala komdlavuza—kubalulekile ekuhleleni ukwelashwa okungewona amangqamuzana amancane omdlavuza wamaphaphu eduze kwami. Lokhu kuhilela ukuhlola okuhlukahlukene, okuhlanganisa ama- imaging scans (CT, PET), ama- biopsies, nokuhlolwa kwegazi. Isiteji sichaza indlela yokwelashwa efanele kakhulu. Isibonelo, i-NSCLC yangaphambi kwesikhathi ingase yelapheke ngokuhlinzwa kuphela, kuyilapho izigaba ezithuthukile zingadinga inhlanganisela yokwelapha.

Izinketho Zokwelashwa ze-NSCLC

Ukuhlinzwa

Ukususwa ngokuhlinzwa kwesimila kuyindlela yokwelapha eyinhloko ye-NSCLC yesigaba sokuqala. Inqubo ethile incike endaweni kanye nobukhulu bethumba. Lokhu kungase kuhlanganise i-lobectomy (ukususwa kwe-lobe yamaphaphu), i-pneumonectomy (ukususwa kwephaphu lonke), noma ukukhishwa kwe-wedge (ukususwa kwengxenye encane yephaphu). Ngemuva kokuhlinzwa, ukuvuselelwa kubalulekile ukuze ululame.

I-Chemotherapy

I-Chemotherapy isebenzisa izidakamizwa ukubulala amangqamuzana omdlavuza. Kuvame ukusetshenziswa ngaphambi kokuhlinzwa (i-neoadjuvant) ukuze kuncishiswe isimila, ngemva kokuhlinzwa (i-adjuvant) ukuze kuqedwe amaseli omdlavuza asele, noma njengokwelashwa okuyinhloko kwe-NSCLC ethuthukisiwe. Imithi ejwayelekile ye-chemotherapy ye-NSCLC ifaka i-cisplatin, i-carboplatin, i-paclitaxel, ne-docetaxel. Imiphumela emibi iyehluka kodwa ivamise ukulawuleka ngokunakekelwa okusekelayo.

Ukwelapha Ngemisebe

Ukwelapha ngemisebe kusebenzisa imisebe enamandla amakhulu ukulimaza nokucekela phansi amangqamuzana omdlavuza. Ingasetshenziswa yodwa, ngaphambi noma ngemva kokuhlinzwa, noma ihlanganiswe ne-chemotherapy. Imisebe ye-beam yangaphandle isetshenziswa kakhulu, iletha imisebe emshinini ongaphandle komzimba. Kwezinye izimo, i-brachytherapy (imisebe yangaphakathi) ingacatshangelwa.

Ukwelapha Okuhlosiwe

Imithi yokwelapha ehlosiwe igxila kuma-molecule athile ngaphakathi kwamangqamuzana omdlavuza, iphazamise ukukhula nokuphila kwawo. Lezi zindlela zokwelapha zisebenza kakhulu ezigulini ze-NSCLC ezinokuguqulwa kwezakhi zofuzo ezithile, njenge-EGFR, ALK, noma ukuguqulwa kwe-ROS1. Ukuhlola okuvamile ukuhlonza lezi zinguquko kubalulekile ukuze kutholwe ukufaneleka kwemithi yokwelapha eqondiwe. Izibonelo zifaka i-Osimertinib (Tagrisso), i-Crizotinib (Xalkori), ne-Afatinib (Gilotrif).

I-Immunotherapy

I-Immunotherapy ihlanganisa amasosha omzimba ukulwa nomdlavuza. Isebenza ngokukhulisa amandla amasosha omzimba okubona nokuhlasela amangqamuzana omdlavuza. Izidakamizwa ze-Immunotherapy, njenge-pembrolizumab (Keytruda) kanye ne-nivolumab (Opdivo), ziyasebenza ezigulini ezithile ze-NSCLC, ngokuvamile zihlanganiswa ne-chemotherapy noma ezinye izindlela zokwelapha. Imiphumela engemihle ingase ihlanganise ukukhathala, ukuqubuka kwesikhumba, nezenzakalo ezimbi ezihlobene nokuzivikela komzimba.

Ukuthola Ukwelashwa Okulungile Eduze Kwawe

Ukukhetha Isikhungo Sokwelapha

Ukukhetha isikhungo se-oncology esifanelekayo kubaluleke kakhulu. Bheka izikhungo ezinodokotela abanolwazi olunzulu nge-oncologists, ubuchwepheshe obuthuthukisiwe, kanye nerekhodi eliqinile ekwelashweni kwe-NSCLC. Cabangela izici ezifana nokuba seduze kwekhaya lakho, isithunzi sesikhungo, nokutholakala kokwelashwa okukhethekile, izivivinyo zomtholampilo, nezinsizakalo zosekelo. Hlola ukubuyekezwa okuku-inthanethi futhi ufune izincomo kudokotela wakho wokunakekela okuyinhloko noma ochwepheshe bezempilo abathembekile.

Izilingo Zomtholampilo

Ukubamba iqhaza ocwaningweni lomtholampilo kunikeza ukufinyelela ekwelashweni okuphambili okungakatholakali kabanzi. Lezi zinhlolo zenzelwe ngokucophelela ukuhlola izindlela zokwelapha ezintsha futhi kuthuthukiswe imiphumela yokwelashwa. I-oncologist yakho ingakusiza ukuthi unqume ukuthi isilingo somtholampilo sisifanele yini isimo sakho esithile. Ungaphinda uhlole imininingwane yolwazi lwesivivinyo somtholampilo njenge-ClinicalTrials.gov ukuze uthole izifundo ezifanele.

Ukusekela Nezinsiza

Ukuzulazula ekuxilongweni komdlavuza kungaba yinselele. Funa ukwesekwa okungokomzwelo nokungokoqobo ngokusebenzisa amaqembu okusekela, izinhlangano zomdlavuza (isb., Inhlangano YaseMelika Yamaphaphu, I-Lung Cancer Foundation of America), kanye nezinsizakalo zokwelulekwa. Lezi zinsiza zinikeza ulwazi olubalulekile, isiqondiso, nokusekelwa ngokomzwelo ezigulini nasemindenini yazo.

Inothi elibalulekile

Lolu lwazi ololwazi jikelele futhi aluhlanganisi iseluleko sezokwelapha. Kubalulekile ukuxhumana ne-oncologist oqeqeshiwe noma uchwepheshe wezokunakekelwa kwezempilo ukuze uthole ukuxilongwa komuntu siqu, ukuhlela ukwelashwa, nokunakekelwa okuqhubekayo okuhlobene ukwelashwa komdlavuza wamaphaphu okungewona omncane. Ulwazi olwethulwa lapha aluthathi iseluleko sochwepheshe bezokwelapha. Ngaso sonke isikhathi funa iseluleko sikadokotela wakho noma omunye umhlinzeki wezempilo oqeqeshiwe nganoma yimiphi imibuzo ongase ube nayo mayelana nesimo sezempilo.

Ukuze uthole ulwazi olwengeziwe noma ukuhlola izinketho zokwelapha esikhungweni esihamba phambili socwaningo lomdlavuza, vakashela I-Shandong Baofa Cancer Research Institute.